| Primary |
| Gastric Cancer |
17.1% |
| Breast Cancer |
16.5% |
| Colorectal Cancer |
10.2% |
| Colon Cancer |
7.0% |
| Drug Use For Unknown Indication |
7.0% |
| Rectal Cancer |
6.5% |
| Neoplasm Malignant |
6.1% |
| Breast Cancer Metastatic |
4.1% |
| Hypertension |
3.7% |
| Pain |
3.4% |
| Metastatic Gastric Cancer |
3.1% |
| Product Used For Unknown Indication |
3.1% |
| Pancreatic Carcinoma |
2.8% |
| Nausea |
2.5% |
| Prophylaxis |
1.9% |
| Colorectal Cancer Metastatic |
1.8% |
| Gastrointestinal Carcinoma |
1.0% |
| Colon Cancer Metastatic |
0.8% |
| Gastrooesophageal Cancer |
0.7% |
| Insomnia |
0.7% |
|
| Death |
30.6% |
| Vomiting |
15.0% |
| Disease Progression |
8.2% |
| Malignant Neoplasm Progression |
6.9% |
| Palmar-plantar Erythrodysaesthesia Syndrome |
4.0% |
| Pyrexia |
3.3% |
| Thrombocytopenia |
3.2% |
| Intestinal Obstruction |
3.0% |
| Sepsis |
3.0% |
| Diarrhoea |
2.8% |
| Mucosal Inflammation |
2.7% |
| Pulmonary Embolism |
2.4% |
| General Physical Health Deterioration |
2.2% |
| Nausea |
2.0% |
| Septic Shock |
1.9% |
| White Blood Cell Count Decreased |
1.9% |
| Weight Decreased |
1.8% |
| Stomatitis |
1.8% |
| Renal Failure |
1.7% |
| Pneumonia |
1.6% |
|
| Secondary |
| Drug Use For Unknown Indication |
13.4% |
| Breast Cancer |
12.8% |
| Gastric Cancer |
11.8% |
| Colon Cancer |
8.0% |
| Colorectal Cancer |
8.0% |
| Breast Cancer Metastatic |
7.0% |
| Colorectal Cancer Metastatic |
6.1% |
| Rectal Cancer |
6.0% |
| Hypertension |
4.0% |
| Prophylaxis |
3.1% |
| Gastrooesophageal Cancer |
2.9% |
| Premedication |
2.6% |
| Product Used For Unknown Indication |
2.4% |
| Pain |
2.3% |
| Oesophageal Carcinoma |
1.8% |
| Colon Cancer Metastatic |
1.8% |
| Nausea |
1.8% |
| Pancreatic Carcinoma |
1.7% |
| Metastatic Gastric Cancer |
1.3% |
| Rectal Cancer Metastatic |
1.2% |
|
| Vomiting |
21.0% |
| Palmar-plantar Erythrodysaesthesia Syndrome |
10.8% |
| Pyrexia |
7.1% |
| Pulmonary Embolism |
5.9% |
| Death |
5.9% |
| Thrombocytopenia |
4.6% |
| Sepsis |
4.5% |
| Diarrhoea |
4.5% |
| Malaise |
3.6% |
| Nausea |
3.5% |
| Neutropenia |
3.4% |
| Intestinal Obstruction |
3.3% |
| White Blood Cell Count Decreased |
3.3% |
| Disease Progression |
3.2% |
| Renal Failure Acute |
3.2% |
| Weight Decreased |
2.7% |
| General Physical Health Deterioration |
2.6% |
| Sudden Death |
2.3% |
| Renal Failure |
2.3% |
| Pneumonia |
2.2% |
|
| Concomitant |
| Breast Cancer |
13.2% |
| Drug Use For Unknown Indication |
12.7% |
| Colorectal Cancer Metastatic |
10.3% |
| Breast Cancer Metastatic |
6.3% |
| Metastases To Bone |
6.1% |
| Gastrooesophageal Cancer |
6.0% |
| Premedication |
5.5% |
| Colon Cancer |
5.0% |
| Rectal Cancer |
4.6% |
| Adenocarcinoma Pancreas |
4.1% |
| Colorectal Cancer |
4.0% |
| Pain |
3.3% |
| Gastric Cancer |
3.2% |
| Product Used For Unknown Indication |
3.2% |
| Colon Cancer Metastatic |
3.1% |
| Chemotherapy |
2.8% |
| Nausea |
2.1% |
| Prophylaxis |
1.7% |
| Hypertension |
1.4% |
| Oesophageal Adenocarcinoma |
1.4% |
|
| Vomiting |
15.0% |
| Palmar-plantar Erythrodysaesthesia Syndrome |
6.7% |
| Weight Decreased |
6.7% |
| Diarrhoea |
6.1% |
| Hospitalisation |
6.1% |
| Pulmonary Embolism |
6.1% |
| Infection |
5.1% |
| Rash |
5.1% |
| Tooth Extraction |
5.1% |
| Nausea |
4.8% |
| Osteonecrosis Of Jaw |
3.7% |
| Neuropathy Peripheral |
3.5% |
| Osteonecrosis |
3.5% |
| Pyrexia |
3.5% |
| Toothache |
3.5% |
| Death |
3.2% |
| Decreased Appetite |
3.2% |
| Hepatic Failure |
3.2% |
| Neutropenic Sepsis |
2.9% |
| Paraesthesia |
2.9% |
|
| Interacting |
| Colon Cancer |
19.4% |
| Rectal Cancer |
13.9% |
| Breast Cancer |
13.0% |
| Colorectal Cancer Metastatic |
11.1% |
| Drug Use For Unknown Indication |
7.4% |
| Epilepsy |
5.6% |
| Product Used For Unknown Indication |
5.6% |
| Bone Lesion |
4.6% |
| Dyspepsia |
3.7% |
| Herpes Zoster |
3.7% |
| Crohn's Disease |
2.8% |
| Complex Partial Seizures |
1.9% |
| Atrial Fibrillation |
0.9% |
| Breast Cancer Metastatic |
0.9% |
| Breast Cancer Recurrent |
0.9% |
| Cerebrovascular Disorder |
0.9% |
| Convulsion Prophylaxis |
0.9% |
| Gallbladder Pain |
0.9% |
| Hypertension |
0.9% |
| Metastases To Bone |
0.9% |
|
| Rash |
18.4% |
| Epilepsy |
10.2% |
| Pyrexia |
8.2% |
| Thrombocytopenia |
8.2% |
| Tooth Discolouration |
8.2% |
| Anticonvulsant Drug Level Increased |
6.1% |
| Drug Interaction |
6.1% |
| Lethargy |
6.1% |
| Renal Failure Acute |
6.1% |
| Blood Bilirubin Increased |
2.0% |
| Blood Creatinine Increased |
2.0% |
| Breast Cancer Metastatic |
2.0% |
| Fatigue |
2.0% |
| Haematuria |
2.0% |
| Malaise |
2.0% |
| Malignant Neoplasm Of Ampulla Of Vater |
2.0% |
| Neuropathy Peripheral |
2.0% |
| Neutropenia |
2.0% |
| Pneumatosis Intestinalis |
2.0% |
| Potentiating Drug Interaction |
2.0% |
|
